ENTA Stock Overview
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ENTA from our risk checks.
My Notes
NewNotes are coming soon
Enanta Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$51.51 |
| 52 Week High | US$79.50 |
| 52 Week Low | US$37.59 |
| Beta | 0.35 |
| 1 Month Change | 13.26% |
| 3 Month Change | 8.67% |
| 1 Year Change | -12.25% |
| 3 Year Change | -0.058% |
| 5 Year Change | -40.98% |
| Change since IPO | 199.83% |
Recent News & Updates
Recent updates
Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term
Nov 25
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?
Oct 25Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?
Jul 04Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Feb 04Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Nov 25Analysts Just Made A Noticeable Upgrade To Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Forecasts
Feb 11Update: Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Gained 85% In The Last Five Years
Jan 23
Earnings Release: Here's Why Analysts Cut Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target To US$61.63
Nov 25Does Enanta Pharmaceuticals (NASDAQ:ENTA) Have A Healthy Balance Sheet?
Nov 24Shareholder Returns
| ENTA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.4% | 1.6% | 3.1% |
| 1Y | -12.2% | 10.5% | -8.5% |
Return vs Industry: ENTA underperformed the US Biotechs industry which returned 10.5% over the past year.
Return vs Market: ENTA underperformed the US Market which returned -8.5% over the past year.
Price Volatility
| ENTA volatility | |
|---|---|
| ENTA Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ENTA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ENTA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 160 | Jay Luly | https://www.enanta.com |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.
Enanta Pharmaceuticals, Inc. Fundamentals Summary
| ENTA fundamental statistics | |
|---|---|
| Market Cap | US$1.07b |
| Earnings (TTM) | -US$121.75m |
| Revenue (TTM) | US$86.16m |
12.4x
P/S Ratio-8.8x
P/E RatioIs ENTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENTA income statement (TTM) | |
|---|---|
| Revenue | US$86.16m |
| Cost of Revenue | US$0 |
| Gross Profit | US$86.16m |
| Other Expenses | US$207.92m |
| Earnings | -US$121.75m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 07, 2023
| Earnings per share (EPS) | -5.85 |
| Gross Margin | 100.00% |
| Net Profit Margin | -141.31% |
| Debt/Equity Ratio | 0.4% |
How did ENTA perform over the long term?
See historical performance and comparison